Results 61 to 70 of about 941,634 (294)
Trends in Incidence of Autoimmune Liver Diseases and Increasing Incidence of Autoimmune Hepatitis.
Clinical Gastroenterology and Hepatology, 2020 BACKGROUND & AIMS Autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) are autoimmune liver diseases of unknown etiology.
M. Lamba, J. Ngu, C. Stedman
semanticscholar +1 more source
Adolescnet Medicine Clinics, 2004 Autoimmune hepatitis affects all ages with a peak incidence in preadolescent girls. The pathogenesis of autoimmune hepatitis has not been defined. Susceptibility, clinical manifestations, and treatment outcomes are affected by environmental factors, individual immunoregulatory responses, genetic factors, age and gender.
Ding-You, Li, Kathleen B, Schwarz
openaire +2 more sources
Pathogens and autoimmune hepatitis [PDF]
Clinical and Experimental Immunology, 2018 Summary Autoimmune hepatitis (AIH) is a severe form of hepatitis resulting in the autoimmune-mediated destruction of the liver parenchyma. Whereas many of the immunopathogenic events have been elucidated and some of the drivers of the disease have been identified, little is known about the aetiology of the disease. There are certain risk
U, Christen, E, Hintermann
openaire +2 more sources
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Journal of Medical Case Reports, 2009 Introduction Q fever is a zoonotic infection that may cause severe hepatitis. Q-fever hepatitis has not yet been associated with autoimmune hepatitis and/or primary biliary cirrhosis.
Kaech Chloe +3 more
doaj +1 more source
Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin +11 more
wiley +1 more source
Drug-induced hepatitis superimposed on the presence of anti-SLA antibody: a case report
Journal of Medical Case Reports, 2008 Introduction Autoimmune hepatitis is a necroinflammatory disorder of unknown etiology characterized by the presence of circulating antibodies, hypergammaglobulinemia, and response to immunosuppression.
Etxagibel Aitziber +4 more
doaj +1 more source
Liver international (Print), 2020 There are few population‐based studies of the incidence and mortality of autoimmune hepatitis. The burden of the disease and how it has changed over time have not been fully explored.
L. Grønbaek +6 more
semanticscholar +1 more source
Pathogenesis of autoimmune hepatitis
World Journal of Hepatology, 2021 Autoimmune hepatitis (AIH) is a chronic progressive liver disease whose etiology and pathogenesis are not yet clear. It is currently believed that the occurrence of AIH is closely related to genetic susceptibility and immune abnormalities, and other factors such as environment, viral infection and drugs that may cause immune dysfunction.
Fan, Jun-Hua +5 more
openaire +2 more sources
Human Pegivirus Encephalitis With Brain Detection and Response to Sofosbuvir Ledipasvir
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Human pegivirus (HPgV‐1) has been associated with severe encephalomyelitis in immunocompromised patients. Its neurological spectrum remains poorly defined. We report a slowly progressive encephalitis in a person living with well‐controlled HIV, characterized by white matter abnormalities and inflammatory cerebrospinal fluid (CSF). HPgV RNA was
Antoine Moulignier +3 more
wiley +1 more source